BAI1-Associated Protein 2-Like 1 (BAIAP2L1) Is a Potential Biomarker in Ovarian Cancer.
BAI1-Associated Protein 2-Like 1 (BAIAP2L1) Is a Potential Biomarker in Ovarian Cancer.
复制标题
DOI：
10.1371/journal.pone.0133081
复制
发表时间：
2015
期刊：
影响因子：
3.7
通讯作者：
Lai CH
中科院分区：
文献类型：
--
作者：
Chao A;Tsai CL;Jung SM;Chuang WC;Kao C;Hsu A;Chen SH;Lin CY;Lee YC;Lee YS;Wang TH;Wang HS;Lai CH
脑特异性血管生成抑制因子1(BAI1)相关蛋白2样蛋白(BAIAP2L1)，又称胰岛素受体酪氨酸激酶底物(IRTKS)，参与细胞形态发生和迁移过程中质膜突起和肌动蛋白的形成。BAIAP2L1最近被报道通过激活EGFR-ERK通路在肝细胞癌中促进细胞增殖。在这项研究中，我们首次报道了BAIAP2L1在人卵巢癌中上调的全面研究。BAIAP2L1在卵巢肿瘤中的上调是在RNA筛选过程中首次发现的，并被卵巢癌和其他癌症类型的免疫组织化学研究证实。通过分析公开可用的数据集中的多个独立队列，验证了BAIAP2L1在卵巢癌中显著上调。BAIAP2L1蛋白在转移灶中的表达高于相应原发灶。卵巢癌细胞的功能分析表明，BAIAP2L1参与促进细胞增殖和避免细胞凋亡。综上所述，本研究结果不仅表明BAIAP2L1可作为人卵巢癌的生物标志物，而且揭示了其在肿瘤生物学中的作用。进一步阐明BAIAP2L1在肿瘤细胞胰岛素受体信号通路中的作用，有助于通过靶向肿瘤特异性代谢来开发癌症治疗药物。
Brain-specific angiogenesis inhibitor 1 (BAI1)-associated protein 2-like 1 (BAIAP2L1), also known as insulin receptor tyrosine kinase substrate (IRTKS), is involved in plasma membrane protrusion and actin formation during cell morphogenesis and migration. BAIAP2L1 is recently reported to promote cell proliferation through activation of the EGFR-ERK pathway in hepatocellular carcinoma. In this study, we report the first comprehensive study of BAIAP2L1 upregulation in human ovarian cancer. Upregulation of BAIAP2L1 in ovarian tumors was first found during RNA screening and confirmed by immunohistochemical studies on ovarian cancers and other cancer types. Significant upregulation of BAIAP2L1 in ovarian cancer was validated by analyzing multiple independent cohorts in publicly available data sets. Furthermore, BAIAP2L1 protein expression in metastatic lesions was higher than the corresponding primary tumors. Functional assays in ovarian cancer cells revealed that BAIAP2L1 is involved in promoting cell proliferation and avoiding apoptosis. In conclusion, results of this study not only indicate that BAIAP2L1 can be used as a biomarker for human ovarian cancer but also reveal its role in cancer biology. Further elucidation of the role of BAIAP2L1 in context of the insulin receptor signaling pathways of cancer cells is warranted for developing cancer therapeutics by targeting cancer-specific metabolism.